Arista group for Blood Loss, Surgical

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Virtua Health System, Marlton, NJ
Blood Loss, Surgical
Arista - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

To examine in Arista hemostatic powder results in less post-total knee arthroplasty blood loss, hematoma formation, and improved range of motion when compared to patients who did not receive the product.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 24 hours postop, 14 days postop, 3 months post op

Month 3
Range of motion
Day 90
Blood Loss
Month 3
Hematoma formation

Trial Safety

Trial Design

2 Treatment Groups

control group
1 of 2
Arista group
1 of 2
Active Control
Experimental Treatment

60 Total Participants · 2 Treatment Groups

Primary Treatment: Arista group · No Placebo Group · Phase 1

Arista group
Drug
Experimental Group · 1 Intervention: Arista · Intervention Types: Drug
control groupNoIntervention Group · 1 Intervention: control group · Intervention Types:
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Arista
2014
N/A
~70

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 24 hours postop, 14 days postop, 3 months post op
Closest Location: Virtua Health System · Marlton, NJ
2015First Recorded Clinical Trial
1 TrialsResearching Blood Loss, Surgical
1 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are between the ages of 18 and 100 years of age.
You are undergoing a primary unilateral total knee arthroplasty.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.